The Role of Neutrophils in Non-Alcoholic Fatty Liver Disease: Mechanisms and Clinical Significance.
1/5 보강
This review methodically elucidates the pivotal role of neutrophils in the pathogenesis and progression of non-alcoholic fatty liver disease (NAFLD).
APA
Zhang F, Li W (2026). The Role of Neutrophils in Non-Alcoholic Fatty Liver Disease: Mechanisms and Clinical Significance.. Journal of inflammation research, 19, 585447. https://doi.org/10.2147/JIR.S585447
MLA
Zhang F, et al.. "The Role of Neutrophils in Non-Alcoholic Fatty Liver Disease: Mechanisms and Clinical Significance.." Journal of inflammation research, vol. 19, 2026, pp. 585447.
PMID
41809765
Abstract
This review methodically elucidates the pivotal role of neutrophils in the pathogenesis and progression of non-alcoholic fatty liver disease (NAFLD). A body of research indicates that neutrophils are preactivated in a background of systemic metabolic dysregulation. Furthermore, neutrophils are specifically recruited to the liver via the CXCR2/CXCL1 axis. In the liver microenvironment, neutrophils directly mediate hepatocyte injury and potently amplify inflammation through synergistic mechanisms. These mechanisms include degranulation, the release of toxic proteases, the production of reactive oxygen species, and the formation of neutrophil extracellular traps. More crucially, neutrophils have been shown to promote disease progression from simple fatty liver to non-alcoholic steatohepatitis, liver fibrosis, and hepatocellular carcinoma by forming complex interaction networks with macrophages, hepatic stellate cells, and hepatocytes. These findings not only deepen our understanding of the immunopathological mechanisms of NAFLD but also highlight the immense clinical translational potential of neutrophils as novel biomarkers and therapeutic targets.
같은 제1저자의 인용 많은 논문 (5)
- Synergistic targeting and stimuli-responsive drug delivery from a dual-network injectable hydrogel for enhanced breast cancer treatment.
- Molecular characterization of early-stage multi-primary lung adenocarcinoma by transcriptome sequencing-a retrospective study.
- First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial.
- Exploring the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer with homologous recombination repair alteration: a meta-analysis based on subgroups and reconstructed individual patient data.
- Circadian Rhythms in Cancer: Mechanistic Insights, Chronotherapeutic Strategies, and Translational Challenges.